Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Organon & Co. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
OGN
New York
2830
www.organon.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Organon & Co.
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
- Jul 31st, 2026 9:00 am
Organon (OGN) Lags Q2 Earnings Estimates
- Jul 31st, 2026 7:45 am
Organon Announces Quarterly Dividend
- Jul 31st, 2026 6:30 am
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
- Jul 28th, 2026 7:00 am
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
- Jul 24th, 2026 6:00 am
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
- Jul 23rd, 2026 9:07 am
Organon (OGN) Names A Canada Chief, Is The Stock Cheap?
- Jul 22nd, 2026 10:34 pm
ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR
- Jul 22nd, 2026 6:02 am
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
- Jul 16th, 2026 5:30 am
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
- Jul 15th, 2026 7:00 am
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
- Jul 7th, 2026 6:00 am
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
- Jul 3rd, 2026 7:00 am
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
- Jun 30th, 2026 7:08 am
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
- Jun 27th, 2026 12:05 pm
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer
- Jun 19th, 2026 1:53 am
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)?
- Jun 15th, 2026 6:17 pm
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential
- Jun 15th, 2026 2:08 am
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
- Jun 12th, 2026 7:15 am
Organon Audit Cleared And New Data Put Valuation And Risks In Focus
- May 25th, 2026 5:08 pm
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
- May 21st, 2026 3:06 am
Scroll